CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
5 mg/500 mg METAGLIP™ Tablets +1 moredrug
Likely dose
5 mg/500 mg METAGLIP™ Tabletsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00834587
NCT00834587Phase 1Completed
CompareCT.gov

A Relative Bioavailability Study of 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets Under Non-Fasting Conditions.

Teva Pharmaceuticals USA·interventional·Posted Feb 3, 2009·Updated Sep 15, 2009

In Brief

A Phase 1 clinical trial evaluating 5 mg/500 mg METAGLIP™ Tablets and 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets for Healthy. Completed, enrolled 40 participants across 2 sites.

Detailed Summary

This study will compare the relative bioavailability (rate and extent of absorption) of 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets manufactured by TEVA Pharmaceutical Industries, Ltd., and distributed by TEVA Pharmaceuticals USA with that of 5 mg/500 mg METAGLIP™ Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 5 mg/500 mg tablet) in healthy adult subjects administered under non-fasting conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 3, 2009
Enrollment StartJun 1, 2004
Primary CompletionJun 1, 2004
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 17.4 years ago

Interventions

5 mg/500 mg METAGLIP™ Tabletsdrug

1 x 5 mg/500 mg, single-dose non-fasting

5 mg/500 mg Glipizide Metformin Hydrochloride Tabletsdrug

1 x 5 mg/500 mg, single-dose non-fasting